24Germline loss-of-function variation in TNFAIP3, encoding A20, has been implicated in a wide 25 variety of autoinflammatory and autoimmune conditions, with acquired somatic missense 26 mutations linked to cancer progression. Furthermore, human sequence data reveals that the A20 27 locus contains ~400 non-synonymous coding variants which are largely uncharacterised. The 28 growing number of A20 coding variants with unknown function, but potential clinical impact, 29 poses a challenge to traditional mouse-based approaches. Here we report the development of a 30 novel functional genomics approach that utilises the new A20-deficient zebrafish (Danio rerio) 31 model to investigate the impact of TNFAIP3 genetic variants in vivo. Similar to A20-deficient 32 mice, A20-deficient zebrafish are hyper-responsive to inflammatory triggers and exhibit 33 spontaneous early lethality. While ectopic addition of human A20 rescued A20-null zebrafish from 34 lethality, missense mutations at two conserved A20 residues, S381A and C243Y reversed this 35 protective effect. Ser381 represents a phosphorylation site important for enhancing A20 activity 36 that is abrogated by its mutation to alanine, or by a C243Y mutation that associates with human 37 autoimmune disease. These data reveal an evolutionarily conserved role for A20, but also 38 demonstrate how a zebrafish functional genomics pipeline can be utilized to investigate the in vivo 39 significance of medically relevant TNFAIP3 gene variants. This approach could be utilised to 40 investigate genetic variation for other conserved genes. 41 42 45activation 2-6 . The medical importance of A20's role in dampening NF-κB is highlighted by cases 46 of germline A20 loss-of-function mutations in humans who present with severe autoinflammatory 47 disease 7,8 , and by the impact of A20 deletion in mice which results in spontaneous and widespread 48 NF-κB activation, multi-organ inflammation and premature lethality 1,9 . The emergence of A20 49 mutations and coding variants as causal genetic factors driving human disease 10,11 highlight the 50 need to better understand A20's functional domains controlling inflammation in vivo. 51 52 A20 suppresses NF-κB signalling with inhibitory activity against key molecular substrates 53 including signalling molecules TNF receptor-associated factor 6 (TRAF6) 9 , receptor interacting 54 protein 1 (RIP1) 12,13 , and the IκB kinase complex (IKK) 14 . The A20 ovarian-tumour (OTU) 55 domain exhibits deubiquitinating editing (DUB) activity cantered on Cys103, which cleaves 56 activating K63-linked ubiquitin chains from RIPK1, TRAF6 and NEMO to terminate NF-κB 57 signalling 9,12,13,15 . The A20 zinc finger 4 (ZnF4) exhibits E3 ligase activity, adding K48-linked 58 ubiquitin chains to RIPK1, triggering RIPK1 proteolysis 12,16 . In addition, the C-terminal ZnF7 59 domain of A20 binds linear ubiquitin to non-catalytically suppress NF-κB activity 17 . A20 is 60 regulated at the level of gene transcription 6 , whereby NF-κB activation induces TNFAIP3 61 expressi...